IRIS UniCatt

Patrono, Carlo
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 4.552
AS - Asia 3.672
EU - Europa 2.952
SA - Sud America 861
Continente sconosciuto - Info sul continente non disponibili 146
AF - Africa 100
OC - Oceania 26
Totale 12.309
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 4.413
SG - Singapore 1.574
CN - Cina 958
BR - Brasile 685
DE - Germania 630
IT - Italia 497
SE - Svezia 496
UA - Ucraina 335
VN - Vietnam 324
FR - Francia 250
IE - Irlanda 194
GB - Regno Unito 174
ID - Indonesia 137
IN - India 121
HK - Hong Kong 112
FI - Finlandia 94
RU - Federazione Russa 93
CA - Canada 70
JP - Giappone 69
BD - Bangladesh 68
AR - Argentina 58
TR - Turchia 48
IQ - Iraq 42
KR - Corea 30
MX - Messico 30
NL - Olanda 29
ZA - Sudafrica 25
ES - Italia 23
PK - Pakistan 23
AT - Austria 22
EC - Ecuador 22
CL - Cile 21
IR - Iran 20
PE - Perù 19
SA - Arabia Saudita 19
CO - Colombia 18
PL - Polonia 18
BE - Belgio 17
PH - Filippine 17
AU - Australia 16
EG - Egitto 15
TH - Thailandia 15
CH - Svizzera 14
MY - Malesia 14
VE - Venezuela 14
PY - Paraguay 12
CZ - Repubblica Ceca 11
CI - Costa d'Avorio 10
JM - Giamaica 10
NZ - Nuova Zelanda 10
UZ - Uzbekistan 10
KE - Kenya 9
MA - Marocco 9
UY - Uruguay 8
BH - Bahrain 7
JO - Giordania 7
NP - Nepal 7
OM - Oman 7
RO - Romania 7
TN - Tunisia 7
AZ - Azerbaigian 6
CR - Costa Rica 6
DZ - Algeria 6
ET - Etiopia 6
IL - Israele 6
LV - Lettonia 6
AE - Emirati Arabi Uniti 5
KZ - Kazakistan 5
NO - Norvegia 5
BO - Bolivia 4
GT - Guatemala 4
HN - Honduras 4
KW - Kuwait 4
LT - Lituania 4
SI - Slovenia 4
SN - Senegal 4
XK - ???statistics.table.value.countryCode.XK??? 4
AL - Albania 3
BY - Bielorussia 3
CG - Congo 3
DO - Repubblica Dominicana 3
MD - Moldavia 3
MK - Macedonia 3
NI - Nicaragua 3
PT - Portogallo 3
SV - El Salvador 3
A1 - Anonimo 2
GE - Georgia 2
HU - Ungheria 2
LI - Liechtenstein 2
PR - Porto Rico 2
PS - Palestinian Territory 2
QA - Qatar 2
RS - Serbia 2
SK - Slovacchia (Repubblica Slovacca) 2
SY - Repubblica araba siriana 2
TJ - Tagikistan 2
AD - Andorra 1
AM - Armenia 1
BA - Bosnia-Erzegovina 1
Totale 12.149
Salva come PNG Salva come JPEG
Città #
Singapore 762
Ashburn 577
San Jose 418
Chandler 408
Beijing 224
Jacksonville 190
Dublin 179
San Mateo 156
Nanjing 134
Jakarta 115
Hangzhou 103
Wilmington 98
Ho Chi Minh City 96
Hong Kong 96
Lauterbourg 95
Los Angeles 93
Cattolica 87
Rome 83
Woodbridge 81
New York 78
Boston 75
Hanoi 75
Milan 74
Ann Arbor 70
Tokyo 65
Lawrence 63
Dallas 60
Moscow 53
Hefei 52
Houston 51
Menlo Park 50
Santa Clara 47
São Paulo 47
Redwood City 45
Buffalo 44
Chicago 42
Nanchang 41
St Louis 41
Munich 40
Dearborn 39
Seattle 38
Frankfurt am Main 37
Fairfield 36
Princeton 36
Boardman 28
Bremen 26
Mountain View 26
Redmond 26
Shenyang 25
Hebei 22
Kunming 22
Lancaster 22
Toronto 22
Izmir 20
Rio de Janeiro 20
Atlanta 19
Da Nang 19
Paris 19
Tianjin 19
Haiphong 18
Bareggio 17
Brussels 17
Guangzhou 17
Helsinki 17
Belo Horizonte 16
Kent 16
London 16
Brasília 15
Seoul 15
Curitiba 14
Guarulhos 14
Hyderabad 14
Orem 14
San Francisco 14
Johannesburg 13
Augusta 12
Denver 12
Dhaka 12
Montreal 12
Norwalk 12
Nuremberg 12
Philadelphia 12
University Park 12
Baghdad 11
Brooklyn 11
Detroit 11
Jiaxing 11
Leawood 11
Lima 11
Naples 11
Nürnberg 11
Porto Alegre 11
Abidjan 10
Bangkok 10
Hounslow 10
Phoenix 10
Vienna 10
Washington 10
Amsterdam 9
Cairo 9
Totale 6.149
Salva come PNG Salva come JPEG
Nome #
The Aspirin Regimens in Essential Thrombocythemia (ARES) phase II randomized trial design: Implementation of the serum thromboxane B(2) assay as an evaluation tool of different aspirin dosing regimens in the clinical setting 298
Postprandial hyperglycemia is a determinant of platelet activation in early type 2 diabetes mellitus. 248
A randomized, double-blind trial of three aspirin regimens to optimize antiplatelet therapy in essential thrombocythemia 230
Antiplatelet agents for the treatment and prevention of atherothrombosis 218
Low-dose aspirin for the prevention of atherothrombosis 207
The recovery of platelet cyclooxygenase activity explains interindividual variability in responsiveness to low-dose aspirin in patients with and without diabetes 194
Long-term pharmacodynamic and clinical effects of twice- versus once-daily low-dose aspirin in essential thrombocythemia: The ARES trial 191
2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC) 191
Prostaglandin E2 differentially modulates human platelet function through the prostanoid EP2 and EP3 receptors 179
Aspirin-insensitive thromboxane biosynthesis in essential thrombocythemia is explained by accelerated renewal of the drug target 178
In Vivo Platelet Activation and Aspirin Responsiveness in Type 1 Diabetes 176
In vivo platelet activation and aspirin responsiveness in type 1 diabetes mellitus 173
Nutraceuticals in diabetes and metabolic syndrome. 167
Patient-independent variables affecting the assessment of aspirin responsiveness by serum thromboxane measurement 163
Increased thromboxane biosynthesis in essential thrombocythemia. 162
The coxibs, selective inhibitors of cyclooxygenase-2 160
Drug insight: aspirin resistance- fact or fashion 154
Aspirin Continues to Attract Research and Debate, 115 Years After Its Synthesis 152
Patient-independent variables affecting the assessment of aspirin responsiveness by serum thromboxane measurement 149
Acute, periprocedural and longterm antithrombotic therapy in older adults: 2022 Update by the ESC Working Group on Thrombosis 149
Oxidative stress and platelet activation in subjects with moderate hyperhomocysteinaemia due to MTHFR 677 C →T polymorphism 148
Platelet activation and atherothrombosis 147
In vivo thromboxane-dependent platelet activation is persistently enhanced in subjects with impaired glucose tolerance 145
Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. 142
ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the Task Force on diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and developed in collaboration with the European Association for the Study of Diabetes (EASD) 142
Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials 136
Determinants of the interindividual variability in response to antiplatelet drugs. 135
Antithrombotic therapy and body mass: an expert position paper of the ESC Working Group on Thrombosis 133
Aspirin: promise and resistance in the new millennium. 132
Aspirin prevents colorectal cancer metastasis in mice by splitting the crosstalk between platelets and tumor cells 131
Non-steroidal anti-inflammatory drugs 124
Thromboxane and prostacyclin biosynthesis in heart failure of ischemic origin: effects of disease severity and aspirin treatment. 123
Low-Dose Aspirin, Coxibs, and other NSAIDS: A clinical Mosaic Emerges. 122
The contribution of cyclooxygenase-1 and -2 to persistent thromboxane biosynthesis in aspirin-treated essential thrombocythemia: implications for antiplatelet therapy 122
Homocysteine, methylenetetrahydrofolate reductase, folate status and atherothrombosis: A mechanistic and clinical perspective 122
In vivo prostacyclin biosynthesis and effects of different aspirin regimens in patients with essential thrombocythaemia 121
Antithrombotic therapy in the elderly: expert position paper of the European Society of Cardiology Working Group on Thrombosis 121
Effects of gastroprotectant drugs for the prevention and treatment of peptic ulcer disease and its complications: a meta-analysis of randomised trials 120
Aspirin in the primary prevention of cardiovascular disease in diabetes mellitus: A new perspective 119
Thromboxane biosynthesis in cancer patients and its inhibition by aspirin: a sub-study of the Add-Aspirin trial 118
Antiplatelet therapy:aspirin for asymptomatic atherosclerosis? 118
Antiplatelet Agents for the Treatment and Prevention of Coronary Atherothrombosis. 118
The future of antiplatelet therapy in cardiovascular disease 116
Cigarette smoking knowledge and perceptions among students in four italian medical schools 115
Association of Platelet Thromboxane Inhibition by Low-Dose Aspirin With Platelet Count and Cytoreductive Therapy in Essential Thrombocythemia 115
Type 2 Diabetes, Obesity, and Aspirin Responsiveness* 114
On-pump Cardiac Surgery Enhances Platelet Renewal and Impairs Aspirin Pharmacodynamics: Effects of Improved Dosing Regimens 113
Thromboxane biosynthesis and future events in diabetes: the ASCEND trial 112
Antiplatelet Drugs: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition) 112
Platelet progenitors: the hidden drug target 112
Efficacy and Safety of Low-Dose Aspirin in Polycythemia Vera 112
Aspirin, 110 years later 109
Eicosanoid biosynthesis and metabolism in myeloproliferative disorders 109
The role of aspirin in cancer prevention 107
Fourth universal definition of myocardial infarction (2018) 107
In vivo thromboxane-dependent platelet activation is persistently enhanced in subjects with impaired glucose tolerance 106
Bleeding and thrombosis in myeloproliferative disorders: mechanisms and treatment 106
Antithrombotic therapy in the elderly: expert position paper of the European Society of Cardiology Working Group on Thrombosis 106
The Key Contribution Of Platelet And Vascular Arachidonic Acid Metabolism To The Pathophysiology Of Atherothrombosis 106
Nonsteroidal antiinflammatory drugs: past, present and future 104
Mechanisms, consequences, and prevention of coronary graft failure 104
Effect of low-dose and standard-dose aspirin on PGE2 biosynthesis among individuals with colorectal adenomas: A randomized clinical trial 103
Aspirin and Other COX-1 Inhibitors 102
Determinants of platelet activation in Alzheimer's disease. 99
Platelet thromboxane inhibition by low-dose aspirin in polycythemia vera: Ex vivo and in vivo measurements and in silico simulation 98
Cyclooxygenase inhibitors: From pharmacology to clinical read-outs 98
Aspirin 96
Aspirin-insensitive thromboxane biosynthesis in essential thrombocythemia is explained by accelerated renewal of the drug target 96
Antithrombotic therapy for patients with atrial fibrillation and atherothrombotic vascular disease: striking the right balance between efficacy and safety 95
Measurement of Thromboxane Biosynthesis in Health and Disease 95
Aspirin 94
Reappraisal of the clinical pharmacology of low-dose aspirin by comparing novel direct and traditional indirect biomarkers of drug action 91
Aspirin in polycythemia vera and essential thrombocythemia: current facts and perspectives. 90
Lipid and protein oxidation contribute to a prothrombotic state in patients with type 2 diabetes mellitus. 89
On-pump Cardiac Surgery Enhances Platelet Renewal and Impairs Aspirin Pharmacodynamics: Effects of Improved Dosing Regimens 89
Cyclooxygenase-2 expression is induced during human megakaryopoiesis and characterizes newly formed platelets 88
Interindividual Variability in response to aspirin and P2Y12 blockers in patients at high cardiovascular risk-the state of the evidence 87
Platelet activation and inhibition in polycythemia vera and essential thrombocythemia. 87
Prostanoids, aspirin and related compounds 86
Low-Dose Aspirin Acetylates Cyclooxygenase-1 in Human Colorectal Mucosa: Implications for the Chemoprevention of Colorectal Cancer 85
Diabetes: Does aspirin increase the risk of major bleeds? 84
The Multifaceted Clinical Readouts of Platelet Inhibition by Low-Dose Aspirin 84
Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials 84
Platelet Cyclooxygenase Inhibition by Low-Dose Aspirin Is Not Reflected Consistently by Platelet Function Assays. Implications for Aspirin "Resistance" 83
Aspirin at 120: Retiring, recombining, or repurposing? 82
The P2Y12 receptor: no active metabolite, no party 80
Low-dose aspirin in primary prevention: cardioprotection, chemoprevention, both, or neither? 79
Precision antiplatelet therapy 78
Coxibs, Traditional NSAIDs, and Cardiovascular Safety Post-PRECISION: What We Thought We Knew Then and What We Think We Know Now 77
Knowledge about health effects of cigarette smoking and quitting among Italian university students: the importance of teaching nicotine dependence and treatment in the medical curriculum 76
Cyclooxygenase-selective inhibition of prostanoid formation: transducing biochemical selectivity into clinical read-outs 76
In Silico Modeling of the Antiplatelet Pharmacodynamics of Low-dose Aspirin in Health and Disease 75
Characterization of biochemical and functional effects of antiplatelet drugs as a key to their clinical development 73
Nonsteroidal anti-inflammatory drugs as anticancer agents: mechanistic, pharmacologic, and clinical issues 73
Distinct roles of prostaglandin H synthases 1 and 2 in T-cell development 72
Nonsteroidal anti-inflammatory drugs and the heart 70
Role of Clinical Pharmacology in the Development of Antiplatelet Drugs 70
Aspirin and Cancer 69
Less Thromboxane, Longer Life 67
Antiplatelet Therapy 66
Totale 11.949
Salva come PNG Salva come JPEG
Categoria #
all - tutte 54.204
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 54.204
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022714 0 74 12 51 62 21 25 128 38 25 112 166
2022/20231.367 209 189 123 164 146 160 37 93 145 23 51 27
2023/2024797 23 235 35 81 36 53 57 30 14 34 91 108
2024/20251.520 34 41 123 51 103 43 32 116 240 135 301 301
2025/20264.395 680 125 329 532 631 212 751 211 271 363 160 130
2026/2027629 386 243 0 0 0 0 0 0 0 0 0 0
Totale 12.309